Background A series of previous reports indicated that tumour necrosis factor-like ligand 1A (TL1A) and its receptor death receptor 3 (DR3) are involved in the pathogenesis of psoriasis vulgaris (PV), which is a common chronic skin disease accompanied by a number of comorbidities, although their exact roles remain unclear. Our previous studies demonstrated that serum TL1A levels were substantially elevated in patients with PV, but the detection of DR3 expression in peripheral blood mononuclear cells (PBMCs) of patients with PV had not been reported. Therefore, we detected DR3 expression on CD4+, CD8+, CD14+ and CD19+ PBMCs of patients with PV, atopic dermatitis (AD) and healthy volunteers.
Methods Blood samples were collected from participants with PV before and after treatment. Then, PBMCs from patients with PV were isolated. The Psoriasis Area Severity Index (PASI) was used to assess severity in patients with PV. The DR3 on CD4+, CD8+, CD14+ and CD19+ PBMCs were detected by flow cytometry analysis. Pearson’s correlation analysis was then used to investigate the relationship between DR3 expression and PASI scores in patients with PV.
Results Comparing with the healthy volunteers and patients with AD, the percentage of DR3-expressing on CD8+ and CD14+ PBMCs in patients with PV was elevated, but the percentage of DR3-expressing on CD8+ and CD14+ cells decreased after anti-inflammatory treatment, which was correlated with PASI scores.
Conclusions Taken together, these findings suggest that DR3 may play a key role in the pathogenesis of PV.
- psoriasis vulgaris
- peripheral blood mononuclear cells
Statistics from Altmetric.com
Contributors LL designed the research, wrote the manuscript and performed the experiments. YoL, LF, PZ, LZ and WW participated in the experimental operations and analysed the data. JN, DW, YaL, BW and YZ critically revised the manuscript for intellectual content and contributed to experimental operations and data analysis. TC designed the research, prepared the funding and submitted the study. All the authors approved the final submitted version.
Funding The National Natural Science Foundation of China (Grant No 81502719) and the Health and Family Planning Commission of Chengdu (Grant No 2015075) supported this project.
Competing interests None declared.
Patient consent Obtained.
Ethics approval The local ethics committees of Chengdu Second People’s Hospital approved this study.
Provenance and peer review Commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.